secwatch / observer
8-K filed April 20, 2023, 7:59 PM ET ticker VERU CIK 0000863894
M&A confidence high sentiment neutral materiality 0.75

VERU INC. (VERU): M&A transaction — Veru sells ENTADFI assets to Blue Water Vaccines for $20M upfront + up to $80M milestones

VERU INC.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

VERU INC. completed a disposition involving Blue Water Vaccines Inc. for $20.0 million (closed 2023-04-19).

Action
disposition
Counterparty
Blue Water Vaccines Inc.
Consideration
$20.0 million
Closing
2023-04-19
Exact text from the filing
purchased substantially all of the assets related to the Company’s ENTADFI ® business. The transaction closed on April 19, 2023. The purchase price for the transaction was $20.0 million, consisting of $6.0 million paid at closing, an additional $4.0 million the Purchaser is obligated to pay the Company in the Company’s fiscal year 2023 and an additional $10
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

VERU INC. entered into Asset Purchase Agreement with Blue Water Vaccines Inc. valued at $20.0 million purchase price: $6.0 million closing, $4.0 million fiscal 2023, $10 million fiscal 202 (effective 2023-04-19).

Action
entry
Agreement
asset purchase
Counterparty
Blue Water Vaccines Inc.
Value
$20.0 million purchase price: $6.0 million closing, $4.0 million fiscal 2023, $10 million fiscal 202
Effective
2023-04-19
Exact text from the filing
On April 19, 2023, the Company entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Blue Water Vaccines Inc. (the “Purchaser”).
View on SEC.gov

15 m&a transactions filed in the last 30 days. Browse all m&a transactions →

VERU INC. filing history →

Source: SEC EDGAR
accession 0001193125-23-107340
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.